CD8(+) T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy

Although immune checkpoint inhibitors (ICIs) are established as effective cancer therapies, overcoming therapeutic resistance remains a critical challenge. Here we identify interleukin 6 (IL-6) as a correlate of poor response to atezolizumab (anti-PD-L1) in large clinical trials of advanced kidney,...

Descripción completa

Detalles Bibliográficos
Autores principales: Huseni, Mahrukh A., Wang, Lifen, Klementowicz, Joanna E., Yuen, Kobe, Breart, Beatrice, Orr, Christine, Liu, Li-fen, Li, Yijin, Gupta, Vinita, Li, Congfen, Rishipathak, Deepali, Peng, Jing, Şenbabaoǧlu, Yasin, Modrusan, Zora, Keerthivasan, Shilpa, Madireddi, Shravan, Chen, Ying-Jiun, Fraser, Eleanor J., Leng, Ning, Hamidi, Habib, Koeppen, Hartmut, Ziai, James, Hashimoto, Kenji, Fassò, Marcella, Williams, Patrick, McDermott, David F., Rosenberg, Jonathan E., Powles, Thomas, Emens, Leisha A., Hegde, Priti S., Mellman, Ira, Turley, Shannon J., Wilson, Mark S., Mariathasan, Sanjeev, Molinero, Luciana, Merchant, Mark, West, Nathaniel R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873827/
https://www.ncbi.nlm.nih.gov/pubmed/36599350
http://dx.doi.org/10.1016/j.xcrm.2022.100878

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873827/
https://www.ncbi.nlm.nih.gov/pubmed/36599350
http://dx.doi.org/10.1016/j.xcrm.2022.100878

Ejemplares similares